![](/img/cover-not-exists.png)
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study
Konecny, Gottfried E, Finkler, Neil, Garcia, Agustin A, Lorusso, Domenica, Lee, Paula S, Rocconi, Rodney P, Fong, Peter C, Squires, Matt, Mishra, Kaushal, Upalawanna, Allison, Wang, Yongyu, KristeleitVolume:
16
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(15)70159-2
Date:
June, 2015
File:
PDF, 554 KB
english, 2015